Augmedix announced preliminary financial results and operational metrics for the fourth quarter of 2022. "Augmedix generated strong bookings in the fourth quarter and we expect revenue to be within our guidance range of $8.5 million to $8.6 million," stated Augmedix, Inc. CEO, Manny Krakaris. "Our current pipeline and backlog should result in continued momentum and a strong start to 2023. Importantly, we are seeing significant expansion within our base of existing clients. Over the last few months, we’ve been encouraged by the increased adoption from larger health system clients." Krakaris added, "Our broad portfolio of solutions is resonating in the market as health systems look to increase patient access, improve productivity, and reduce clinician burnout. Augmedix’s solutions address each of these systemic challenges, and we are well positioned to maintain our robust growth while simultaneously expanding our operating leverage, to achieve our ultimate goal of substantial cash generation." The below preliminary data is as of December 31, 2022, unless otherwise noted. Annual Recurring Revenue of $35 million. 1,300 clinicians in service, up 39% year-over-year. Revenue in the fourth quarter of 2022 is expected to be within the guidance range of $8.5 million to $8.6 million.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on AUGX:
